March 27th 2024
This treatment is now the first and only TMS treatment that is FDA-cleared for this patient population.
March 20th 2024
Here's how embracing a comprehensive, patient-centered approach and staying informed about emerging treatments can help mental health professionals make a difference in the lives of patients with TRD.
The Expanding Role of Fluid Biomarkers in the Diagnosis and Management of Patients With Alzheimer Disease
View More
Clinical Consultations™: Considerations for Customizing Care Plans for Patients with Parkinson Disease Psychosis
View More
Expert Illustrations & Commentaries™: Visualizing New Therapeutic Targets in Schizophrenia
View More
Advances In™ Schizophrenia: Expanding the Therapeutic Landscape
View More
Southern California Psychiatry Conference
September 13-14, 2024
Register Now!
Updates on New and Emerging Therapies to Improve Outcomes for Patients With Major Depressive Disorder
View More
2023 Annual Psychiatric Times™ World CME Conference
View More
5th Annual International Congress on the Future of Neurology®
View More
Enhancing Patients' Motivation and Empowerment: A Resident’s Perspective
March 22nd 2024Empowerment has a significant correlation with patients’ overall mental and physical well-being, and has been central to the shift in conceptual framework of mental illness recovery towards a focus on resilience, strength, and control over one’s life.
Augmentation Strategies for Treatment-Resistant Depression
March 19th 2024Given that two-thirds of patients treated for a major depressive episode will fail to achieve remission of symptoms after 2 or more treatment trials of first-line antidepressants, the probability of remission will further decrease with subsequent medication trials. Treatment strategies for patients with TRD include augmentation, where a medication is added to a current antidepressant versus switching to a different antidepressant.
The Relationship Between Glucose Fluctuations and Cognition in Patients With Type 1 Diabetes
A new study found that when glucose is either very high or low in patients with type 1 diabetes, cognition is slower; however, slightly above average glucose led to peak cognitive performance.